IL2 and non-small cell lung carcinoma: recently reported that increased serological levels of IFN-γ and TNF-α next to IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and IL-12, resulted in better responses with longer survival upon anti-PD-1 therapy in NSCLC patients (29).